ReviewJournal of the National Cancer Institute2010
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?
Review in Journal of the National Cancer Institute, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 172 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
172 citing papers in PubMed, 5 syntheses or guidelines pooled it, 419 citations in OpenAlex.
- Guidelines for breast cancer management in Bosnia and Herzegovina.Biomolecules & biomedicine · 2023Guideline
- Survival Benefit of Surgical Treatment Added Into Systemic Treatment for Isolated Breast Cancer Liver Metastases: A Systematic Review and Meta-Analysis.Frontiers in surgery · 2021Pooled it
- Incidence of central nervous system metastases in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with trastuzumab: A meta-analysis.Clinics (Sao Paulo, Brazil) · 2021Pooled it
- The role of liver resection in patients with metastatic breast cancer: a systematic review examining the survival impact.Irish journal of medical science · 2018Pooled it
- Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review.Journal of experimental & clinical cancer research : CR · 2013Pooled it
- A 6-Week Program to Strengthen Resiliency Among Women With Metastatic Cancer: A Randomized Clinical Trial.The oncologist · 2023Trial
- Effects of Continuous Care Combined with Evidence-Based Nursing on Mental Status and Quality of Life and Self-Care Ability in Patients with Liver from Breast Cancer: A Single-Center Randomized Controlled Study.Computational and mathematical methods in medicine · 2022Trial
- Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial.Breast (Edinburgh, Scotland) · 2020Trial
- Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.The oncologist · 2013Trial
- Local Ablative Therapy in Breast Cancer Liver Metastases: Survival Outcomes and Prognostic Factors-A Single-Center Retrospective Study.Journal of clinical medicine · 2026Article
- Metastatic breast cancer outcome in a real-world setting: analysis for long-term survival and curability in a prospective dataset.The oncologist · 2026Article
- NKGD2 Ligands (NKG2DLs) in Breast Cancer: In Silico Analysis and Narrative Review.International journal of molecular sciences · 2026Review
- Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.Nature communications · 2026Article
- Targeted Delivery of Lidocaine in Breast Cancer Cells via Zeolitic Imidazolate Framework-8 Nanoparticles.Chemphyschem : a European journal of chemical physics and physical chemistry · 2025Article
- First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data.Journal of clinical medicine · 2025Article
- Article
- Simultaneous integrated boost intensity-modulated radiotherapy for treatment of bone metastases: analysis of a breast cancer cohort.Acta oncologica (Stockholm, Sweden) · 2025Article
- Investigation of the efficacy and safety of lung biopsy plus microwave ablation for a solitary suspected malignant pulmonary nodule after radical mastectomy.Frontiers in oncology · 2025Article
- Underserved Patient Populations With Metastatic Breast Cancer: A Review of Progress and Remaining Challenges.The breast journal · 2025Review
- Breast cancer metastasis progression is associated with elevated activity of kynurenine monooxygenase and kynureninase.British journal of cancer · 2024Article
112 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A distinctive subset of metastatic breast cancer (MBC) is oligometastatic disease, which is characterized by single or few detectable metastatic lesions. The existing treatment guidelines for patients with localized MBC include surgery, radiotherapy, and regional chemotherapy. The European School of Oncology-Metastatic Breast Cancer Task Force addressed the management of these patients in its first consensus recommendations published in 2007. The Task Force endorsed the possibility of a more aggressive and multidisciplinary approach for patients with oligometastatic disease, stressing also the need for clinical trials in this patient population. At the sixth European Breast Cancer Conference, held in Berlin in March 2008, the second public session on MBC guidelines addressed the controversial issue of whether MBC can be cured. In this commentary, we summarize the discussion and related recommendations regarding the available therapeutic options that are possibly associated with cure in these patients. In particular, data on local (surgery and radiotherapy) and chemotherapy options are discussed. Large retrospective series show an association between surgical removal of the primary tumor or of lung metastases and improved long-term outcome in patients with oligometastatic disease. In the absence of data from prospective randomized studies, removal of the primary tumor or isolated metastatic lesions may be an attractive therapeutic strategy in this subset of patients, offering rapid disease control and potential for survival benefit. Some improvement in outcome may also be achieved with optimization of systemic therapies, possibly in combination with optimal local treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.